Drug-eluting stents for the treatment of acute myocardial infarction: the view to the HORIZONS.
Drug-eluting stents (DES) offer an attractive option for the treatment of acute thrombotic lesions during acute ST-elevation myocardial infarction (STEMI) due to their ability to inhibit restenosis. Several randomised trials have demonstrated the efficacy of DES in reducing target vessel revascularisation (TVR) in this setting. However, several registries of real-world patients receiving DES for STEMI have raised long-term safety concerns about DES use in this patient subset. Given the inherent limitations of registry data, this issue is likely to remain unresolved until further data is made available from large-scale ongoing trials with long-term follow-up such as the HORIZONS-AMI trial.
Prasad
Sandhir B
SB
MonashHeart and Monash Cardiovascular Research Centre, Monash Medical Centre, 246 Clayton Road, Melbourne, Vic 3168, Australia.
Ahmar
Walid
W
Malaiapan
Yuvaraj
Y
Meredith
Ian T
IT
D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D023903:Coronary Restenosis / Q000517:prevention & control* / Q000628:therapy; D054855:Drug-Eluting Stents; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000517:prevention & control / Q000628:therapy*; D017239:Paclitaxel / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D020123:Sirolimus / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus